Sugi Predict

Sugi Predict / Compounds / SCHEMBL2856019

SCHEMBL2856019

SCHEMBL2856019

OCC1(c2ccccc2)CCCCC1

nearest known ligand 0.64

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 1/20 0.61
▸ SLC6A4 P31645 4/20 0.58
▸ SLC6A2 P23975 3/20 0.58
▸ SLC6A3 Q01959 3/20 0.58
▸ LMNA P02545 3/20 0.50
▸ L3MBTL1 Q9Y468 2/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ NPSR1 Q6W5P4 1/20 0.49
▸ MAOA P21397 1/20 0.48
▸ MAOB P27338 1/20 0.48
▸ TAAR1 Q96RJ0 1/20 0.48
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ AKR1C1 Q04828 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1152119 0.98 DPP4 (0.63) DPP4SLC6A4SLC6A2SLC6A3LMNA
SCHEMBL7333210 0.93 DPP4 (0.57) DPP4SLC6A4SLC6A2SLC6A3LMNA
Ammonia Solution, Strong SCHEMBL7260918 0.91 DPP4 (0.55) DPP4SLC6A4SLC6A2SLC6A3LMNA
SCHEMBL1371770 0.89 MAOA (0.60) DPP4SLC6A4SLC6A2SLC6A3LMNA
SCHEMBL8706024 0.81 ESR2 (0.57) DPP4SLC6A4SLC6A2SLC6A3
SCHEMBL3898162 0.81 MAOA (0.47) DPP4SLC6A4SLC6A2SLC6A3LMNA
SCHEMBL28438976 0.79 SLC6A4 (0.67) SLC6A4SLC6A2SLC6A3
SCHEMBL435866 0.79 SLC6A3 (0.67) SLC6A4SLC6A2SLC6A3
SCHEMBL6867538 0.79 MAOA (0.45) DPP4SLC6A4SLC6A2SLC6A3LMNA
SCHEMBL1038938 0.79 TACR1 (0.56) SLC6A4SLC6A2MAOAMAOBTAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115557836-A Preparation method of carboxylic acid 云南大学 2023-01-03 — — CN claimed
CN-106977368-A A kind of synthetic method of optical voidness phenylcyclohexyl methanol 康化（上海）新药研发有限公司 2017-07-25 — — CN claimed
CN-115557836-A Preparation method of carboxylic acid 云南大学 2023-01-03 — — CN disclosed
CN-109535155-B Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases 艾伯维公司 2022-07-12 — — CN disclosed
US-20210346369-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC. (US) 2021-11-11 — — US disclosed
US-20200345717-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC. (US) 2020-11-05 — — US disclosed
CN-109535155-A Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases 艾伯维公司 2019-03-29 — — CN disclosed
CN-103958508-B Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases 艾伯维公司 2019-02-12 — — CN disclosed
CN-108976100-A The synthetic method of diphenylcyclohexylcarbinol 浙江大学 2018-12-11 — — CN disclosed
EP-2768830-B1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC (US) 2018-08-29 — — EP disclosed
US-20180221363-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC (US) 2018-08-09 — — US disclosed
US-7202253-B2 Cycloalkyl inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-10 — — US disclosed
CN-1732146-A Cycloalkyl inhibitors of potassium channel function BRISTOL MYERS SQUIBB CO (US) 2006-02-08 — — CN disclosed
US-20050234106-A1 Cycloalkyl inhibitors of potassium channel function LLOYD JOHN 2005-10-20 — — US disclosed
WO-2005095544-A1 LIQUID CRYSTAL COMPOUNDS, LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY MERCK PATENT GMBH (DE) 2005-10-13 — — WO disclosed
EP-1507504-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION Bristol-Myers Squibb Company (US) 2005-02-23 — — EP disclosed
US-20040072880-A1 Cycloalkyl inhibitors of potassium channel function ICAGEN, INC. 2004-04-15 — — US disclosed
WO-2003063797-A2 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2003-08-07 — — WO disclosed
CN-1113840-C Synthesis method of alpha-hydroxycyclohexylbenzyl ketone SHI CAIYUN (CN) 2003-07-09 — — CN disclosed
US-5331010-A TREATING MAMMALS FOR CONVULSIONS THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) 1994-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200345717-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES BAX, BCL2, BCL3 DPP4 3803/4885SLC6A4 4840/4885SLC6A2 4871/4885
US-20050234106-A1 Cycloalkyl inhibitors of potassium channel function KCNJ2, KCNN3, KCNQ5 DPP4 2095/4885SLC6A4 1950/4885SLC6A2 2579/4885
US-20210346369-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES BAX, BCL2, BCL3 DPP4 3803/4885SLC6A4 4840/4885SLC6A2 4871/4885
US-20180221363-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES BAX, BCL2, BCL3 DPP4 3803/4885SLC6A4 4840/4885SLC6A2 4871/4885
US-20040072880-A1 Cycloalkyl inhibitors of potassium channel function KCNN1, KCNN2, KCNH2 DPP4 2381/4885SLC6A4 1539/4885SLC6A2 1870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.